Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 Plus FOLFOX in Advanced GI Malignancies
NCT02102022Phase 2Terminated
- Sponsor
- Polaris Group
- Start
- Nov 2014
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of Pegargiminase in hepatocellular carcinoma (HCC), gastric cancer (GC), colorectal cancer (CRC), sponsored by Polaris Group. Started Nov 2014; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02102022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102022.